Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients

被引:31
作者
Bello, Caroline [1 ]
Roseth, Arne [2 ]
Guardiola, Jordi [3 ]
Reenaers, Catherine [1 ]
Ruiz-Cerulla, Alexandra [3 ]
Van Kemseke, Catherine [1 ]
Arajol, Claudia [3 ]
Reinhard, Christian [4 ]
Seidel, Laurence [5 ]
Louis, Edouard [1 ]
机构
[1] Univ Hosp CHU Liege, Dept Gastroenterol, Liege, Belgium
[2] Lovisenberg Diaconal Hosp, Sect Gastroenterol, Dept Med, Oslo, Norway
[3] Hosp Univ Bellvitge IDIBELL, Dept Gastroenterol, Barcelona, Spain
[4] BUHLMANN Labs AG, Schonenbuch, Switzerland
[5] CHU Liege, Dept Biostat & Medicoecon Informat, Univ Hosp, Liege, Belgium
关键词
Fecal calprotectin; Home-based test; Inflammatory bowel disease; Self-care; Usability; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; INTRAINDIVIDUAL VARIABILITY; INDEX; CARE;
D O I
10.1016/j.dld.2017.05.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients. Methods: IBD patients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA. Results: Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88. Conclusion: The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA. (C) 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:991 / 996
页数:6
相关论文
共 22 条
  • [11] Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
    Kristensen, Vendel
    Malmstrom, Gunn Helen
    Skar, Viggo
    Roseth, Arne
    Moum, Bjorn
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (05) : 548 - 555
  • [12] The Intra-Individual Variability of Faecal Calprotectin: A Prospective Study In Patients With Active Ulcerative Colitis
    Lasson, Anders
    Stotzer, Per-Ove
    Ohman, Lena
    Isaksson, Stefan
    Sapnara, Maria
    Strid, Hans
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (01) : 26 - 32
  • [13] Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity
    Lin, Jin-Feng
    Chen, Jin-Min
    Zuo, Jun-Hua
    Yu, Allen
    Xiao, Zhu-Jun
    Deng, Fei-Hong
    Nie, Biao
    Jiang, Bo
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (08) : 1407 - 1415
  • [14] Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study
    Ong, Woon May
    Chua, Siew Siang
    Ng, Chirk Jenn
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 237 - 246
  • [15] eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease
    Pedersen, N.
    Elkjaer, M.
    Duricova, D.
    Burisch, J.
    Dobrzanski, C.
    Andersen, N. N.
    Jess, T.
    Bendtsen, F.
    Langholz, E.
    Leotta, S.
    Knudsen, T.
    Thorsgaard, N.
    Munkholm, P.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (09) : 840 - 849
  • [16] Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
    Peyrin-Biroulet, L.
    Sandborn, W.
    Sands, B. E.
    Reinisch, W.
    Bemelman, W.
    Bryant, R. V.
    D'Haens, G.
    Dotan, I.
    Dubinsky, M.
    Feagan, B.
    Fiorino, G.
    Gearry, R.
    Krishnareddy, S.
    Lakatos, P. L.
    Loftus, E. V., Jr.
    Marteau, P.
    Munkholm, P.
    Murdoch, T. B.
    Ordas, I.
    Panaccione, R.
    Riddell, R. H.
    Ruel, J.
    Rubin, D. T.
    Samaan, M.
    Siegel, C. A.
    Silverberg, M. S.
    Stoker, J.
    Schreiber, S.
    Travis, S.
    Van Assche, G.
    Danese, S.
    Panes, J.
    Bouguen, G.
    O'Donnell, S.
    Pariente, B.
    Winer, S.
    Hanauer, S.
    Colombel, J. -F.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (09) : 1324 - 1338
  • [17] Does telemonitoring in heart failure empower patients for self-care? A qualitative study
    Riley, Jillian P.
    Gabe, Jonathan P. N.
    Cowie, Martin R.
    [J]. JOURNAL OF CLINICAL NURSING, 2013, 22 (17-18) : 2444 - 2455
  • [18] Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes
    Schoepfer, Alain M.
    Beglinger, Christoph
    Straumann, Alex
    Safroneeva, Ekaterina
    Romero, Yvonne
    Armstrong, David
    Schmidt, Carsten
    Trummler, Michael
    Pittet, Valerie
    Vavricka, Stephan R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) : 332 - 341
  • [19] Information Technology to Support Self-Management in Chronic Care A Systematic Review
    Solomon, Michael R.
    [J]. DISEASE MANAGEMENT & HEALTH OUTCOMES, 2008, 16 (06) : 391 - 401
  • [20] Fecal Calprotectin Measured By Patients at Home Using Smartphones-A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease
    Vinding, Kristoffer Kofod
    Elsberg, Henriette
    Thorkilgaard, Tine
    Belard, Erika
    Pedersen, Natalia
    Elkjaer, Margarita
    Marker, Dorte
    Carlsen, Katrine
    Burisch, Johan
    Munkholm, Pia
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 (02) : 336 - 344